However, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have changed the game altogether for individuals with advanced ovarian cancer, especially those carrying breast cancer (BRCA1/2) mutations or so-called homologous recombination deficiencies (HRDs) [1]. This evidence concerns the gene BRCA1 and ovarian carcinoma.